EOS imaging (Paris:EOSI)(Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging and associated solutions, announces that Gérard Hascoët, appointed as a Board member at the company’s last Shareholders’ Meeting, became Chairman of the Board on July 10.
An eminent figure in the medical device sector, Gérard Hascoët brings more than 30 years of entrepreneurial and international experience to support EOS imaging’s development strategy.
Mr. Hascoët began his career within the medical technology branch of Thomson CGR. A serial entrepreneur, he founded in 1985 Technomed International, now within EDAP TMS, dedicated to non-invasive medical treatment in urology. In 1993, he founded Sometec, a hemodynamic monitoring company divested to Arrow International, and IMMI, a neurosurgical robotics company divested to ISS. From 2008 to 2011, Gérard was CEO of SpineVision, a spinal implant company of which he still is Board member. In 2009, he cofounded MD Start, a European incubator for medical technology companies, of which he is currently Executive Chairman. Gérard is also Venture Partner of Sofinnova, one of the leading European healthcare venture firms.
Mr. Hascoët succeeds to Mike J. Dormer, Chairman of the Company’s Board since 2012.
“Since 2012, EOS imaging has executed a remarkable growth strategy and I am delighted that an entrepreneur as talented as Gérard Hascoët will now be helping the Company continue this development,” Dormer said.
Marie Meynadier, CEO of EOS imaging, adds: “We are very happy with our achievements over the last three years and extremely thankful to Mike’s support over that decisive period. Gérard Hascoët’s strategic vision and entrepreneurial expertise in medical devices will be key assets to the company’s progress in establishing a leadership position in orthopedic solutions based on imaging.”
The EOS® system provides full-body stereo-radiographic images of patients in functional positions, in both 2D and 3D. EOS exams require a radiation dose 50% to 85% less than Digital Radiology and 95% less than basic CT scans, as well as related software solutions. The new EOS Micro Dose option, recently cleared by the Food and Drug Administration, allows a further drastic step towards the ALARA principle (As Low As Reasonably Achievable) by bringing pediatric spine follow up exams at a dose level equivalent to a week of natural background radiation on Earth.
For further information about the Company or EOS®, the first full body, low dose 2D/3D imaging system, please visit http://www.eos-imaging.com/.
EOS imaging has been chosen to be included in the new EnterNext© PEA-PME 150 index, composed of 150 French companies and listed on Euronext and Alternext markets in Paris.
EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI
Next press release: results for the 1st half of 2015, on 1 September, 2015
About EOS imaging:
EOS imaging designs, develops, and markets EOS®, an innovative medical imaging system based on technology that enabled Georges Charpak to win the Nobel Prize for Physics, as well as associated solutions. The Company is authorized to market in 48 countries, including the United States (FDA), Japan and the European Union (EU). As of December 31, 2014 the Group posted 2014 consolidated revenue of €20.1 million and employed 107 people including an R&D team of 39 engineers. The Group is based in Paris and holds five subsidiaries in Besançon (France), Cambridge (Massachusetts), Montreal (Canada) and Frankfurt (Germany), and Singapore.
Source and image credit: EOS imaging
